LeeKing and Jritch90.
I don't think there would be a trading halt for BAU orders - reading the prez from Aug and statements in the AGM - this is for the single US$6.9M which was in proposal/ closing stage for a very large clinical trail (maybe the Cartesian study ?).
This single company changing order (~ A$10M), is a game changer and worthy of a TH - it means that apart from our BAU revenue ~A$5M, there is another revenue stream for 2X this. This means that revenue for 2023 could be in total 3X (~ A$15M). Not sure if this is a 1 year value only (and therefore may not be repeated in 2024), or may be signs of things to come (Andwin trial, pre-eclampsia, etc) where rev will be at a new level based on diversified trial data (because of changed trials since CV19).
That's my reading in any case - let's see what is announced in a few days. In any case even if rev over the forward 12 months is an extra A$10-12M (total rev A$15M+), this will still see the company being re-rated and the SP moving up.
As to short term SP - my prediction is back to the CR @ 50c and even higher with an uptrend towards the $1 - 1.50 mark. I base this on the hurdles the directors set for the incentive shares.
Anyways ..... GLTAH, we're moving now.
Add to My Watchlist
What is My Watchlist?
